BioTrack Capital
博远资本
BioTrack Capital (博远资本) is a China-based life-sciences investor that shows up in elsewhere's corpus almost exclusively through its biotech deal activity rather than any profile of the fund itself. The throughline is healthcare across stages: it co-led DeepKinase's Series A alongside 龙磐投资 in 2023 , joined Inming Biotech's angel round back in 2021 with LAV and 峰瑞资本 , participated in Minghui Pharmaceutical's $131M pre-IPO round co-led by OrbiMed and Qiming in 2025 , and continued backing existing portfolio companies like 欧科健 through its 2025 Series B . It has also ranged slightly beyond therapeutics — co-leading TanSheng WanWu's Series A for direct-air-capture-based sustainable aviation fuel with Gaorong in mid-2026 . Beyond this deal footprint, the corpus doesn't cover the fund's founding, team, or AUM.
AI-generated — may contain errors, please verify.
Coverage
Wanwu Capital Portfolio Company TanSheng WanWu Completes Series A Funding to Accelerate Direct Air Carbon Capture for Sustainable Aviation Fuel Production
"CO₂ is the oil of the new era."
5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
Qiming Venture Partners co-leads $30M Series B in Shenzhen Oculgen, first-in-class bispecific OCUL101 enters Phase II in China and US
Focused on R&D of innovative ophthalmic drugs
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Minghui Pharmaceutical Raises $131M in Pre-IPO Round Co-Led by Qiming Venture Partners
Minghui Pharmaceutical is a late-stage biopharmaceutical company focused on oncology and autoimmune diseases.
From Angel to G+ Round: 5 Early-Stage FreeS Fund Portfolio Companies Raise Over 3 Billion RMB | FreeS Family Funding News · Vol 14
Looking forward to working alongside more outstanding founders.
Qitan Tech Closes RMB 700 Million Series C Round to Advance Commercialization of Domestic Nanopore Sequencing Technology
Breaking Through the "Mass-Production No-Man's-Land" of Domestic Nanopore Sequencing
FreeS Family Funding News · July | PatPat, Yanming Biotech, Qbit, and Innostar Secure Financing
We've also released three short videos this issue — follow us to check them out.
FreeS Family Funding News · April | OnKure Therapeutics, IceKredit, Duanyu Liangjin, and Jiuzhou Yunjian Secure Funding
New Column Launch
